Horizon Pharma Files Patent Infringement Lawsuits For Filing Pennsaid 2% ANDA

(RTTNews) - Biopharmaceutical company Horizon Pharma plc (HZNP) announced it has filed patent infringement lawsuits in the U.S. District Court for the District of New Jersey related to Abbreviated New Drug Applications or ANDA filed with the U.S. Food and Drug Administration to market a generic version of Pennsaid or diclofenac sodium topical solution 2% w/w.

The lawsuit was filed against Actavis Laboratories UT, Inc., Actavis, Inc., and Allergan plc, as well as Amneal Pharmaceuticals, LLC, IGI Laboratories, Inc., Lupin Ltd. and Lupin Pharmaceuticals, Inc., as well as Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd.

The lawsuits claim infringement of Horizon's newly issued U.S. Patent No. 9,066,913 titled "Diclofenac Topical Formulation," which covers Pennsaid 2%. These lawsuits are the second patent litigations filed against these defendants relating to Pennsaid 2%.

Pennsaid 2% w/w is a non-steroidal anti-inflammatory drug indicated for the treatment of pain of osteoarthritis of the knees.